在急性肺损伤中,生物模拟的菌菌体用于有效的粘液透和肺向
Xiangrong Dai1, Yi Liao1, Rong Chen1
1Postgraduate Training Base Alliance of Wenzhou Medical University, Whenzhou 325000, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China.
Acta biomaterialia
|March 13, 2026
概括
开发出来的超小的zwiterionic micelles (D-PCBn) 通过改善粘液透和肺部保留来增强肺部药物输送. 这些新型纳米颗粒显示出治疗肺部疾病具有减少副作用的前景.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 肺部药物输送 肺部药物输送
背景情况:
- 肺部药物输送面临诸多挑战,包括粘膜细胞清除和巨细胞化,限制治疗效果.
- 由于这些障碍,传统的吸入配方因肺部保留和生物可用性不佳而扎.
研究的目的:
- 为增强肺部药物输送开发超小的紫菌体 (D-PCBn).
- 将仿生向与改善的粘膜透进行协同,以更好地保留肺部.
主要方法:
- 合成的迪斯泰洛酸乙醇胺 (DSPE) - 块聚 (N-甲基烯酸氧乙烯-N,N-二甲基氨酸-α-N-甲基碳酸) (CB) 米塞尔 (D-PCBn).
- 使用模仿双基酸胆 (DPPC) 的 DSPE 核心和用于粘液透的 carboxybetaine 冠状.
- 评估D-PCB30变体载有德甲在小鼠模型通过气溶给药.
主要成果:
- 经过优化D-PCB30小粒的检测,显示出优异的粘液透,肺部沉积和甲封装.
- 在体内研究显示,肺部积累增强,停留时间延长,全身分布减少.
- 转录组分析揭示了调节的炎症路径和巨细胞两极分化 (M1到M2) 的转变.
结论:
- D-PCBn粒体代表了一个有希望的可吸入纳米平台,用于向治疗肺部疾病.
- "伪装和滑"的策略有效地克服了肺部障碍.
- 在治疗炎症性肺部疾病方面,已经证明了增强的治疗疗效和有利的生物安全性.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
291
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
291
01:30Micelles
132
Micelle formation is an intricate process that hinges on the properties of amphiphilic or amphipathic molecules and the conditions of the system in which they are found. Amphiphilic molecules, which have both hydrophilic (water-attracting) and hydrophobic (water-repelling) parts, play a critical role in this process.In aqueous environments, these molecules arrange themselves such that their hydrophilic heads are turned towards the water phase, while their hydrophobic tails are oriented away...
132
01:29Acute Respiratory Failure-V
611
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
611